Aldeyra Therapeutics(DE:137)
€0.55-0.02 (-2.68%)
DE:137
Aldeyra Therapeutics financials statements
€0.55
At close:-0.02 (-2.68%)
Aldeyra Therapeutics (137) Ratios
0 Followers
Aldeyra Therapeutics Ratios
DE:137's free cash flow for Q3 2026 was $-4.12M. For the 2026 fiscal year, DE:137's free cash flow was increased by $0.00 and operating cash flow was $-4.12M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.58 | 5.59 | 6.64 | 11.78 | 19.77 |
| Quick Ratio | 2.58 | 5.59 | 6.64 | 11.78 | 19.77 |
| Cash Ratio | 2.52 | 2.93 | 6.42 | 9.40 | 19.52 |
| Solvency Ratio | -1.21 | -1.65 | -1.31 | -2.04 | -2.10 |
| Operating Cash Flow Ratio | -1.20 | -2.32 | -1.36 | -3.69 | -3.61 |
| Short-Term Operating Cash Flow Coverage | -2.19 | -1377.30 | -2.00 | -62.12 | 0.00 |
| Net Current Asset Value | $ 43.97M | $ 70.47M | $ 119.28M | $ 150.74M | $ 205.35M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.22 | 0.15 | 0.11 | 0.09 | 0.07 |
| Debt-to-Equity Ratio | 0.35 | 0.22 | 0.13 | 0.11 | 0.08 |
| Debt-to-Capital Ratio | 0.26 | 0.18 | 0.12 | 0.10 | 0.07 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.17 | 0.00 | 0.09 | 0.07 |
| Financial Leverage Ratio | 1.63 | 1.47 | 1.24 | 1.20 | 1.13 |
| Debt Service Coverage Ratio | -1.85 | -27.42 | -2.04 | -23.05 | -32.01 |
| Interest Coverage Ratio | -18.51 | -31.21 | -20.66 | -37.00 | -32.27 |
| Debt to Market Cap | 0.05 | 0.05 | 0.07 | 0.04 | 0.07 |
| Interest Debt Per Share | 0.29 | 0.29 | 0.30 | 0.30 | 0.33 |
| Net Debt to EBITDA | 1.72 | 0.73 | 3.61 | 2.14 | 3.84 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 95.98% | 92.90% | 87.73% | 98.95% | 102.77% |
| Return on Assets (ROA) | -46.97% | -53.39% | -25.31% | -34.21% | -24.78% |
| Return on Equity (ROE) | -76.49% | -78.66% | -31.34% | -41.07% | -28.08% |
| Return on Capital Employed (ROCE) | -79.69% | -69.90% | -33.95% | -37.77% | -25.40% |
| Return on Invested Capital (ROIC) | -58.99% | -69.65% | -30.25% | -37.51% | -25.37% |
| Return on Tangible Assets | -46.97% | -53.39% | -25.31% | -34.21% | -24.78% |
| Earnings Yield | -10.88% | -18.82% | -18.15% | -15.26% | -26.73% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.56 | -0.73 | -0.51 | -0.97 | -0.79 |
| Free Cash Flow Per Share | -0.56 | -0.73 | -0.51 | -0.97 | -0.79 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | 0.00 | -3471.05 | -5451.69 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | -3471.05 | -5451.69 |
| Operating Cash Flow Coverage Ratio | -2.15 | -2.82 | -1.94 | -3.52 | -2.68 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -10.72% | -14.56% | -14.66% | -13.94% | -19.69% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -9.25 | -5.31 | -5.51 | -6.55 | -3.74 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 7.03 | 4.18 | 1.73 | 2.69 | 1.05 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -9.33 | -6.87 | -6.82 | -7.18 | -5.08 |
| Price-to-Operating Cash Flow Ratio | -9.33 | -6.87 | -6.82 | -7.18 | -5.08 |
| Price-to-Earnings Growth (PEG) Ratio | 0.23 | -0.11 | 0.14 | 7.01 | 1.04 |
| Enterprise Value Multiple | -8.10 | -4.80 | -2.26 | -4.63 | -0.04 |
| Enterprise Value | 256.58M | 257.61M | 79.72M | 278.17M | 2.24M |
| EV to EBITDA | -8.10 | -4.80 | -2.26 | -4.63 | -0.04 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -7.69 | -5.96 | -2.63 | -4.91 | -0.05 |
| EV to Operating Cash Flow | -7.69 | -5.96 | -2.63 | -4.91 | -0.05 |
| Tangible Book Value Per Share | 0.74 | 1.19 | 2.03 | 2.59 | 3.81 |
| Shareholders’ Equity Per Share | 0.74 | 1.19 | 2.03 | 2.59 | 3.81 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.56 | -0.94 | -0.64 | -1.06 | -1.07 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.06 | 1.04 | 1.06 | 1.03 | 1.03 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.99 | 0.77 | 0.81 | 0.91 | 0.74 |
Currency in USD
